NCT04623021 - A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

December 12, 2020

Study Completion Date

December 12, 2020

Conditions

COVID-19

Interventions

DRUG

Nafamostat Mesilate

Administered intravenously as a continuous infusion

Trial Locations (11)

A108_02CVD2014 Site# 9, Barnaul

A108_02CVD2014 Site# 26, Krasnoyarsk

A108_02CVD2014 Site# 5, Moscow

A108_02CVD2014 Site# 8, Moscow

A108_02CVD2014 Site# 31, Ryazan

A108_02CVD2014 Site# 25, Saint Petersburg

A108_02CVD2014 Site# 29, Saint Petersburg

A108_02CVD2014 Site# 30, Saint Petersburg

A108_02CVD2014 Site# 3, Saint Petersburg

A108_02CVD2014 Site# 4, Saint Petersburg

A108_02CVD2014 site#1, Ufa